Svetlana Nikic, Founder of Precision Oncology Consulting, shared a post on LinkedIn:
“The 50th anniversary of the European Society for Medical Oncology (ESMO) Congress, ESMO25, showcased how fast oncology is transforming toward data-driven, biomarker-guided care.
Our comprehensive analysis, now live, summarizes data from selected 60+ abstracts across leading diagnostic developers and testing providers, alongside key clinical breakthroughs shaping therapy selection.
By the numbers:
- Natera – 16 abstracts: Multi-tumor ctDNA MRD evidence confirming Signatera as a predictive biomarker guiding adjuvant immunotherapy and treatment de-escalation.
- Guardant Health – 15 abstracts: Validation of Guardant Reveal as a plasma-only MRD test across CRC, lung, and head-and-neck cancers — with decision-impact data showing how ctDNA results change oncologist behavior.
- Foundation Medicine – 12 abstracts: Multi-omic CGP (DNA + RNA) defining HRD signatures, ESR1/AR-V7 fusions, and resistance pathways across ovarian, breast, and rare tumors.
- Tempus AI – 6 abstracts: Integration of AI, RNA-based subtyping, and real-world data to personalize therapy in renal, prostate, and lung cancer.
- Bio-Rad Laboratories-Rad – 6 abstracts: Digital PCR (ddPCR) emerging as a scalable hospital-based platform for MRD quantification and resistance monitoring.
Beyond the data, ESMO 2025 reflected several defining trends:
- MRD maturity: More than 25 studies showed ctDNA or methylation-based MRD assays moving from validation to clinical decision-making — including adjuvant therapy guidance and recurrence monitoring.
- Convergence of diagnostics and therapeutics: Multi-omic CGP and ctDNA results increasingly featured in prospective interventional trials, blurring lines between biomarker discovery and clinical practice.
- Policy momentum: New cost-effectiveness and implementation models (France, Ireland, Norway) show how genomic testing is becoming embedded in health-system strategy, not just research.
- Therapy innovation: ADCs, bispecific IO combinations, and radioligand therapies continued to expand treatment frontiers, supported by biomarker-driven trial designs.
Explore the full Precision Oncology Consulting ESMO 2025 Takeaways, including company-level summaries, policy analyses, and therapeutic highlights.
In our analysis, we’ve included only the companies for which we’ve had easy access to the presented data. If you’d like your company to be featured in future editions, do reach out! Filtering on the ESMO congress website remains, let’s say… a bit of a challenge.”
You can find more posts featuring Svetlana Nikic on OncoDaily.